654 related articles for article (PubMed ID: 17135646)
1. Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer.
O'Brien ME; Ciuleanu TE; Tsekov H; Shparyk Y; Cuceviá B; Juhasz G; Thatcher N; Ross GA; Dane GC; Crofts T
J Clin Oncol; 2006 Dec; 24(34):5441-7. PubMed ID: 17135646
[TBL] [Abstract][Full Text] [Related]
2. Phase III study of oral compared with intravenous topotecan as second-line therapy in small-cell lung cancer.
Eckardt JR; von Pawel J; Pujol JL; Papai Z; Quoix E; Ardizzoni A; Poulin R; Preston AJ; Dane G; Ross G
J Clin Oncol; 2007 May; 25(15):2086-92. PubMed ID: 17513814
[TBL] [Abstract][Full Text] [Related]
3. Open-label, multicenter, randomized, phase III study comparing oral topotecan/cisplatin versus etoposide/cisplatin as treatment for chemotherapy-naive patients with extensive-disease small-cell lung cancer.
Eckardt JR; von Pawel J; Papai Z; Tomova A; Tzekova V; Crofts TE; Brannon S; Wissel P; Ross G
J Clin Oncol; 2006 May; 24(13):2044-51. PubMed ID: 16648504
[TBL] [Abstract][Full Text] [Related]
4. Phase II trial of amrubicin for treatment of refractory or relapsed small-cell lung cancer: Thoracic Oncology Research Group Study 0301.
Onoda S; Masuda N; Seto T; Eguchi K; Takiguchi Y; Isobe H; Okamoto H; Ogura T; Yokoyama A; Seki N; Asaka-Amano Y; Harada M; Tagawa A; Kunikane H; Yokoba M; Uematsu K; Kuriyama T; Kuroiwa Y; Watanabe K;
J Clin Oncol; 2006 Dec; 24(34):5448-53. PubMed ID: 17135647
[TBL] [Abstract][Full Text] [Related]
5. A multi-center phase II study of weekly topotecan as second-line therapy for small cell lung cancer.
Shah C; Ready N; Perry M; Kirshner J; Gajra A; Neuman N; Garziano S
Lung Cancer; 2007 Jul; 57(1):84-8. PubMed ID: 17399850
[TBL] [Abstract][Full Text] [Related]
6. Topotecan and etoposide as first-line therapy for extensive disease small cell lung cancer: a phase II trial of a platinum-free regimen.
Reck M; Groth G; Buchholz E; Goetz E; Gatzemeier U; Manegold C
Lung Cancer; 2005 Jun; 48(3):409-13. PubMed ID: 15893010
[TBL] [Abstract][Full Text] [Related]
7. Phase III study comparing oral topotecan to intravenous docetaxel in patients with pretreated advanced non-small-cell lung cancer.
Ramlau R; Gervais R; Krzakowski M; von Pawel J; Kaukel E; Abratt RP; Dharan B; Grotzinger KM; Ross G; Dane G; Shepherd FA
J Clin Oncol; 2006 Jun; 24(18):2800-7. PubMed ID: 16682727
[TBL] [Abstract][Full Text] [Related]
8. Randomized phase II trial comparing amrubicin with topotecan in patients with previously treated small-cell lung cancer: North Japan Lung Cancer Study Group Trial 0402.
Inoue A; Sugawara S; Yamazaki K; Maemondo M; Suzuki T; Gomi K; Takanashi S; Inoue C; Inage M; Yokouchi H; Watanabe H; Tsukamoto T; Saijo Y; Ishimoto O; Hommura F; Nukiwa T
J Clin Oncol; 2008 Nov; 26(33):5401-6. PubMed ID: 18854562
[TBL] [Abstract][Full Text] [Related]
9. A phase II study of higher dose weekly topotecan in relapsed small-cell lung cancer.
Spigel DR; Greco FA; Burris HA; Shipley DL; Clark BL; Whorf RC; Arrowsmith ER; Hainsworth JD
Clin Lung Cancer; 2011 May; 12(3):187-91. PubMed ID: 21663862
[TBL] [Abstract][Full Text] [Related]
10. A phase I and pharmacological study of amrubicin and topotecan in patients of small-cell lung cancer with relapsed or extensive-disease small-cell lung cancer.
Shibayama T; Hotta K; Takigawa N; Tada A; Ueoka H; Harita S; Kiura K; Tabata M; Segawa Y; Nogami N; Kuyama S; Shinkai T; Tanimoto M
Lung Cancer; 2006 Aug; 53(2):189-95. PubMed ID: 16806573
[TBL] [Abstract][Full Text] [Related]
11. A randomised phase II study of the efficacy and safety of intravenous topotecan in combination with either cisplatin or etoposide in patients with untreated extensive disease small-cell lung cancer.
Quoix E; Breton JL; Gervais R; Wilson J; Schramel F; Cardenal F; Ross G; Preston A; Lymboura M; Mattson K
Lung Cancer; 2005 Aug; 49(2):253-61. PubMed ID: 16022920
[TBL] [Abstract][Full Text] [Related]
12. Phase II NCCTG trial of oral topotecan and paclitaxel with G-CSF (filgrastim) support in patients with previously untreated extensive-stage small cell lung cancer.
Molina JR; Jett JR; Foster N; Lair BS; Carroll TJ; Tazelaar HD; Hillman S; Mailliard JA; Bernath AM; Nikcevich D
Am J Clin Oncol; 2006 Jun; 29(3):246-51. PubMed ID: 16755177
[TBL] [Abstract][Full Text] [Related]
13. Quality-of-life considerations in patients with advanced lung cancer: effect of topotecan on symptom palliation and quality of life.
Gralla RJ
Oncologist; 2004; 9 Suppl 6():14-24. PubMed ID: 15616146
[TBL] [Abstract][Full Text] [Related]
14. Phase II trial of second-line bendamustine chemotherapy in relapsed small cell lung cancer patients.
Schmittel A; Knödler M; Hortig P; Schulze K; Thiel E; Keilholz U
Lung Cancer; 2007 Jan; 55(1):109-13. PubMed ID: 17097191
[TBL] [Abstract][Full Text] [Related]
15. Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a Gynecologic Oncology Group Study.
Long HJ; Bundy BN; Grendys EC; Benda JA; McMeekin DS; Sorosky J; Miller DS; Eaton LA; Fiorica JV;
J Clin Oncol; 2005 Jul; 23(21):4626-33. PubMed ID: 15911865
[TBL] [Abstract][Full Text] [Related]
16. Topotecan and cisplatin in combination with concurrent twice-daily chemoradiation in limited disease small cell lung cancer-a Danish Oncological Lung Cancer Group (DOLG) phase II trial.
Sorensen M; Lassen U; Palshof T; Jensen BB; Johansen J; Jensen PB; Langer SW
Lung Cancer; 2008 May; 60(2):252-8. PubMed ID: 18036701
[TBL] [Abstract][Full Text] [Related]
17. Combination of topotecan and cisplatin in relapsed patients with small cell lung cancer: a phase II study of the hellenic cooperative oncology group (HeCOG).
Christodoulou C; Kalofonos HP; Briasoulis E; Bafaloukos D; Makatsoris T; Koutras A; Skarlos DV; Samantas E
Cancer Chemother Pharmacol; 2006 Jan; 57(2):207-12. PubMed ID: 16028103
[TBL] [Abstract][Full Text] [Related]
18. Phase III trial of pemetrexed plus best supportive care compared with best supportive care in previously treated patients with advanced malignant pleural mesothelioma.
Jassem J; Ramlau R; Santoro A; Schuette W; Chemaissani A; Hong S; Blatter J; Adachi S; Hanauske A; Manegold C
J Clin Oncol; 2008 Apr; 26(10):1698-704. PubMed ID: 18375898
[TBL] [Abstract][Full Text] [Related]
19. Topotecan in the treatment of recurrent small cell lung cancer: an update.
Ardizzoni A
Oncologist; 2004; 9 Suppl 6():4-13. PubMed ID: 15616145
[TBL] [Abstract][Full Text] [Related]
20. Hematologic safety and tolerability of topotecan in recurrent ovarian cancer and small cell lung cancer: an integrated analysis.
Armstrong DK; Spriggs D; Levin J; Poulin R; Lane S
Oncologist; 2005 Oct; 10(9):686-94. PubMed ID: 16249347
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
